Prostate Cancer

Coalition to Focus on Health Disparities Black Men with Prostate Cancer Face

September 28th 2020, 3:00pm

Forward Momentum, a coalition launched by a biopharmaceutical company and three partners, focuses on the health disparities faced by Black men with prostate cancer.

Friday Frontline: Smartphone app encourages smoking cessation, House passes Veteran’s Prostate Cancer Treatment and Research Act, and More

September 25th 2020, 3:00pm

From a new study showing that the iCanQuit smoking cessation app is more likely to work than typical guidelines, to the House unanimously passing the Veteran’s Prostate Cancer Treatment and Research Act, here’s what’s happening in the cancer landscape this week.

Lynparza Significantly Improves Survival in Subset of Patients with Metastatic Prostate Cancer

September 23rd 2020, 1:00pm

The PARP inhibitor Lynparza reduced the risk for death by 31% in men with metastatic castration-resistant prostate cancer compared with Xtandi or Zytiga plus the corticosteroid prednisone.

Expert Connections: Hereditary Prostate Cancer

September 16th 2020, 7:40pm

CURE® Speaking Out Launches Video Series in Recognition of National Prostate Cancer Awareness Month

September 8th 2020, 3:44pm

Charles J. Ryan, M.D., internationally recognized for his research on prostate cancer, discusses risk factors, treatments and racial disparities associated with the disease.

The Latest News and Updates in Prostate Cancer

September 5th 2020, 2:00pm

A roundup of the latest news and updates for patients with prostate cancer from CURE®.

Discussing Trends in Prostate Cancer

September 1st 2020, 1:00pm

On behalf of ZERO - The End of Prostate Cancer, CURE spoke with Dr. Charles Ryan about prostate cancer – including the basics, genetics of the disease, developments in advanced prostate cancer and racial disparities.

Genetics Remains Paramount for Moving Rare Cancers Forward

August 30th 2020, 2:00pm

The evolving understanding of cancer genetics is allowing for clinicians to look at how to move rare cancer treatments, and identifications, forward.

FDA Offers Feedback on Phase 3 Trial Design of VERU-111 in Prostate Cancer

August 26th 2020, 1:00pm

The Food and Drug Administration noted the trial design was acceptable for researchers to evaluate VERU-111 in in metastatic castration and novel androgen-blocking agent resistant prostate cancer.

Friday Frontline: Pediatric Cancer Research Legislation Goes Into Effect, MLB Hall of Famer Cal Ripken Jr. Announces He is Cancer Free and More

August 21st 2020, 3:00pm

From the bi-partisan Research to Accelerate Cures and Equity (RACE) for Children Act implementing an FDA mandate that all new cancer therapies for adults must also be studied in children, to the “Iron Man” of baseball Cal Ripken Jr. announcing he’s cancer free after a February diagnosis, here’s what’s happening in the cancer landscape this week.